세계의 면역성 혈소판 감소증 시장 보고서(2025년)

Immune Thrombocytopenia Global Market Report 2025

US $ 4,490 ￦ 6,430,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,294,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,159,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 면역성 혈소판 감소증 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 예측 기간의 주요 동향으로는 진단 기술의 진보, 디지털 헬스 솔루션의 통합, 병용 요법으로의 전환 , 원격 의료의 채용, 진단에 있어서의 인공지능의 도입 등을 들 수 있습니다.

자가면역 질환의 유병률 증가는 향후 면역성 혈소판 감소증 시장의 성장을 가속할 것으로 예측됩니다. 자가 면역 질환 증가는 유전적 요인, 환경의 영향, 라이프 스타일의 변화, 진단의 개선으로 이어지는 인지도의 향상 등의 요인에 의한 것으로 예측됩니다. 자기면역질환은 면역계가 혈소판을 공격 및 파괴하거나 골수에서의 혈소판 생산을 저해함으로써 면역성 혈소판 감소증을 일으킵니다.

면역성 혈소판감소증 시장 진출기업은 치료결과 개선, 반응시간 단축, 환자 어드히어런스 향상, 혈소판감소증 관리 미충족 요구 대응 등을 목적으로 특히 정맥 내(IV) 요법에서 치료 옵션의 진전에 주력하고 있습니다. 2024년 3월, Argenx SE는 일본 후생노동성이 성인 원발성 면역성 혈소판감소증(ITP)의 정맥내 투여에 VYVGART를 승인했다고 발표했습니다. 이 승인은 신속한 효과와 지속적인 혈소판 반응성을 가진 표적 접근법을 제공하고자가 면역 질환 치료에서 중요한 격차를 해결하고 치료에 중요한 진보를 의미합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 면역성 혈소판 감소증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 면역성 혈소판 감소증 시장 : 성장률 분석
• 세계의 면역성 혈소판 감소증 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 면역성 혈소판 감소증 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 면역성 혈소판 감소증 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 면역성 혈소판 감소증 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 1차성 면역혈소판 감소증
• 이차성 면역혈소판 감소증
• 후천성 면역혈소판 감소증
• 세계의 면역성 혈소판 감소증 시장 : 치료 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 코르티코스테로이드
• 정맥내 면역글로불린
• 트롬보포이에틴 수용체 작용제
• 면역억제요법
• 세계의 면역성 혈소판 감소증 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 면역성 혈소판 감소증 시장 : 1차성 면역 혈소판 감소증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 급성 원발성 ITP
• 만성 원발성 ITP
• 지속성 1차성 ITP
• 세계의 면역성 혈소판 감소증 시장 : 2차성 면역 혈소판 감소증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 약물 유발성 ITP
• 감염 관련 ITP
• 자가면역 질환 관련 ITP
• 세계의 면역성 혈소판 감소증 시장 : 후천성 면역 혈소판 감소증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 면역 개재성 후천성 ITP
• 비면역성 ITP

제7장 지역별/국가별 분석

• 세계의 면역성 혈소판 감소증 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 면역성 혈소판 감소증 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 면역성 혈소판 감소증 시장 : 경쟁 구도
• 면역성 혈소판 감소증 시장 : 기업 프로파일
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Sanofi SA
  • Novartis AG
  • Amgen Inc.

제31장 기타 주요 기업 및 혁신 기업

• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Intas Pharmaceuticals Ltd.
• CSL Behring
• Griffols
• UCB Pharma
• Kyowa Kirin
• Sobi(Swedish Orphan Biovitrum)
• 3SBio Inc.
• BIoTest AG
• Shionogi & Co. Ltd.
• Ligand Pharmaceuticals
• Rigel Pharmaceuticals
• Symphogen
• Hansa Biopharma

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

• 면역성 혈소판 감소증 시장, 2029년 : 새로운 기회를 제공하는 국가
• 면역성 혈소판 감소증 시장, 2029년 : 새로운 기회를 제공하는 부문
• 면역성 혈소판 감소증 시장, 2029년 : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

JHS

영문 목차

영문목차

Immune thrombocytopenia is a rare autoimmune bleeding disorder in which the immune system mistakenly attacks and destroys platelets, which are crucial for blood clotting. This results in a low platelet count, impairing the blood's ability to form clots. Common symptoms include easy bruising, bleeding, and a rash consisting of small red spots.

The primary types of immune thrombocytopenia are primary immune thrombocytopenia (ITP), secondary immune thrombocytopenia, and acquired immune thrombocytopenia. Primary ITP occurs when the immune system incorrectly targets and eliminates platelets in the blood. Treatment options for ITP include intravenous immunoglobulin, thrombopoietin receptor agonists, and immunosuppressive therapy, which are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The immune thrombocytopenia market research report is one of a series of new reports from The Business Research Company that provides immune thrombocytopenia market statistics, including the immune thrombocytopenia industry's global market size, regional shares, competitors with a immune thrombocytopenia market share, detailed immune thrombocytopenia market segments, market trends and opportunities, and any further data you may need to thrive in the immune thrombocytopenia industry. This immune thrombocytopenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immune thrombocytopenia market size has grown strongly in recent years. It will grow from $3.43 billion in 2024 to $3.64 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to factors such as the rising prevalence of autoimmune disorders, an increase in the incidence of chronic liver diseases, greater access to healthcare services, expansion of healthcare infrastructure, and growing government support.

The immune thrombocytopenia market size is expected to see strong growth in the next few years. It will grow to $4.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of thrombocytopenia, rising healthcare spending, the expansion of available therapies, a growing prevalence of blood disorders, and an aging population. Key trends in the forecast period include advancements in diagnostic technologies, the integration of digital health solutions, a shift toward combination therapies, the adoption of telemedicine, and the incorporation of artificial intelligence in diagnostics.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the immune thrombocytopenia market in the future. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues, treating them as foreign invaders. This abnormal immune response causes inflammation and damage to various organs and systems. The rise in autoimmune diseases can be attributed to factors such as genetic predispositions, environmental influences, lifestyle changes, and greater awareness leading to improved diagnosis. Autoimmune diseases can cause immune thrombocytopenia by prompting the immune system to attack and destroy platelets or interfere with their production in the bone marrow. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a prevalence rate of 8.61%. Therefore, the increasing prevalence of autoimmune diseases is contributing to the growth of the immune thrombocytopenia market.

Companies in the immune thrombocytopenia market are focusing on advancing therapeutic options, especially in intravenous (IV) therapies, to improve treatment outcomes, reduce response times, increase patient adherence, and address unmet needs in thrombocytopenia management. IV therapy involves delivering fluids, medications, or nutrients directly into a patient's vein through an intravenous line. For instance, in March 2024, Argenx SE, a biotechnology company based in the Netherlands, announced that the Japan Ministry of Health, Labor, and Welfare (MHLW) had approved VYVGART for intravenous administration in adults with primary immune thrombocytopenia (ITP). This approval marks a significant advancement in treatment, offering a targeted approach with rapid effects and sustained platelet response, addressing key gaps in autoimmune disease treatment.

In December 2024, Keros Therapeutics Inc., a U.S.-based biopharmaceutical company, formed a partnership with Takeda Pharmaceutical Industries Ltd. to develop and commercialize elritercept, a therapy designed to target disorders related to dysfunctional TGF-B signaling, including thrombocytopenia and other rare diseases. Takeda Pharmaceutical Industries Ltd., a Japan-based biopharmaceutical company, specializes in innovative treatments for thrombocytopenia and other rare diseases.

Major players in the immune thrombocytopenia market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Amgen Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Intas Pharmaceuticals Ltd., CSL Behring, Griffols, UCB Pharma, Kyowa Kirin, Sobi (Swedish Orphan Biovitrum), 3SBio Inc., Biotest AG, Shionogi & Co. Ltd., Ligand Pharmaceuticals, Rigel Pharmaceuticals, Symphogen, Hansa Biopharma, and Argenx.

North America was the largest region in the immune thrombocytopenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the immune thrombocytopenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immune thrombocytopenia market consists of revenues earned by entities by providing services such as blood or platelet transfusions, splenectomy, plasma exchange, monitoring, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The immune thrombocytopenia market also includes sales of pharmaceutical drugs, diagnostic kits and reagents, medical devices, platelet transfusion products, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immune Thrombocytopenia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immune thrombocytopenia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immune thrombocytopenia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immune thrombocytopenia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Primary Immune Thrombocytopenia; Secondary Immune Thrombocytopenia; Acquired Immune Thrombocytopenia
• 2) By Treatment Type: Intravenous Immunoglobulin; Thrombopoietin Receptor Agonists; Immunosuppressive Therapy
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Primary Immune Thrombocytopenia: Acute Primary ITP; Chronic Primary ITP; Persistent Primary ITP
• 2) By Secondary Immune Thrombocytopenia: Drug-Induced ITP; Infection-Associated ITP; Autoimmune Disorder-Related ITP
• 3) By Acquired Immune Thrombocytopenia: Immune-Mediated Acquired ITP; Non-Immune Acquired ITP
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Novartis AG; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immune Thrombocytopenia Market Characteristics

3. Immune Thrombocytopenia Market Trends And Strategies

4. Immune Thrombocytopenia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Immune Thrombocytopenia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Immune Thrombocytopenia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Immune Thrombocytopenia Market Growth Rate Analysis
• 5.4. Global Immune Thrombocytopenia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Immune Thrombocytopenia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Immune Thrombocytopenia Total Addressable Market (TAM)

6. Immune Thrombocytopenia Market Segmentation

• 6.1. Global Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Immune Thrombocytopenia
• Secondary Immune Thrombocytopenia
• Acquired Immune Thrombocytopenia
• 6.2. Global Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Intravenous Immunoglobulin
• Thrombopoietin Receptor Agonists
• Immunosuppressive Therapy
• 6.3. Global Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Immune Thrombocytopenia Market, Sub-Segmentation Of Primary Immune Thrombocytopenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Primary ITP
• Chronic Primary ITP
• Persistent Primary ITP
• 6.5. Global Immune Thrombocytopenia Market, Sub-Segmentation Of Secondary Immune Thrombocytopenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug-Induced ITP
• Infection-Associated ITP
• Autoimmune Disorder-Related ITP
• 6.6. Global Immune Thrombocytopenia Market, Sub-Segmentation Of Acquired Immune Thrombocytopenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune-Mediated Acquired ITP
• Non-Immune Acquired ITP

7. Immune Thrombocytopenia Market Regional And Country Analysis

• 7.1. Global Immune Thrombocytopenia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Immune Thrombocytopenia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Immune Thrombocytopenia Market

• 8.1. Asia-Pacific Immune Thrombocytopenia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Immune Thrombocytopenia Market

• 9.1. China Immune Thrombocytopenia Market Overview
• 9.2. China Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Immune Thrombocytopenia Market

• 10.1. India Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Immune Thrombocytopenia Market

• 11.1. Japan Immune Thrombocytopenia Market Overview
• 11.2. Japan Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Immune Thrombocytopenia Market

• 12.1. Australia Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Immune Thrombocytopenia Market

• 13.1. Indonesia Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Immune Thrombocytopenia Market

• 14.1. South Korea Immune Thrombocytopenia Market Overview
• 14.2. South Korea Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Immune Thrombocytopenia Market

• 15.1. Western Europe Immune Thrombocytopenia Market Overview
• 15.2. Western Europe Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Immune Thrombocytopenia Market

• 16.1. UK Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Immune Thrombocytopenia Market

• 17.1. Germany Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Immune Thrombocytopenia Market

• 18.1. France Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Immune Thrombocytopenia Market

• 19.1. Italy Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Immune Thrombocytopenia Market

• 20.1. Spain Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Immune Thrombocytopenia Market

• 21.1. Eastern Europe Immune Thrombocytopenia Market Overview
• 21.2. Eastern Europe Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Immune Thrombocytopenia Market

• 22.1. Russia Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Immune Thrombocytopenia Market

• 23.1. North America Immune Thrombocytopenia Market Overview
• 23.2. North America Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Immune Thrombocytopenia Market

• 24.1. USA Immune Thrombocytopenia Market Overview
• 24.2. USA Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Immune Thrombocytopenia Market

• 25.1. Canada Immune Thrombocytopenia Market Overview
• 25.2. Canada Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Immune Thrombocytopenia Market

• 26.1. South America Immune Thrombocytopenia Market Overview
• 26.2. South America Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Immune Thrombocytopenia Market

• 27.1. Brazil Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Immune Thrombocytopenia Market

• 28.1. Middle East Immune Thrombocytopenia Market Overview
• 28.2. Middle East Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Immune Thrombocytopenia Market

• 29.1. Africa Immune Thrombocytopenia Market Overview
• 29.2. Africa Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Immune Thrombocytopenia Market Competitive Landscape And Company Profiles

• 30.1. Immune Thrombocytopenia Market Competitive Landscape
• 30.2. Immune Thrombocytopenia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Immune Thrombocytopenia Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Eli Lilly and Company
• 31.3. Intas Pharmaceuticals Ltd.
• 31.4. CSL Behring
• 31.5. Griffols
• 31.6. UCB Pharma
• 31.7. Kyowa Kirin
• 31.8. Sobi (Swedish Orphan Biovitrum)
• 31.9. 3SBio Inc.
• 31.10. Biotest AG
• 31.11. Shionogi & Co. Ltd.
• 31.12. Ligand Pharmaceuticals
• 31.13. Rigel Pharmaceuticals
• 31.14. Symphogen
• 31.15. Hansa Biopharma

32. Global Immune Thrombocytopenia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Immune Thrombocytopenia Market

34. Recent Developments In The Immune Thrombocytopenia Market

35. Immune Thrombocytopenia Market High Potential Countries, Segments and Strategies

• 35.1 Immune Thrombocytopenia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Immune Thrombocytopenia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Immune Thrombocytopenia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료